Venous thromboembolism in heparin-induced thrombocytopenia

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 4, 2000, Pages 343-351

  Warkentin, Theodore E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARIN; LEPIRUDIN; WARFARIN;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; GANGRENE; HUMAN; LUNG EMBOLISM; PATHOGENESIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0033942288     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200007000-00016     Document Type: Review

References (61)

1. 1 Warkentin TE: Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 1999, 50;129-147.
2. 2 Warkentin TE: Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999, 82 (Suppl.): 439-447.
3. 3 Amiral J, Bridey F, Dreyfus M, et al.: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia [letter]. Thromb Haemost 1992, 68:95-96.
4. 4 Greinacher A, Pötzsch B, Amiral J, et al.: Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994, 71:247-251.
5. 5 Horne MK, Hutchison KJ: Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998, 58:24-30.
6. 6 Ziporen L, Li ZQ, Park KS, et al.: Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998, 92:3250-3259.
7. 7 Visentin GP, Moghaddam M, Aster RH: Antibodies associated with heparin-induced thrombocytopenia/thrombosis (HITP) recognize sites on platelet factor 4 (PF4) induced by the binding of linear polyanionic compounds [abstract]. Thromb Haemost 1997, 77(Suppl.):362.
8. 8 Visentin GP, Bacsi S, Aster RH: Molecular immunopathogenesis of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker Inc., 2000:139-154.
9. 9 Chong BH, Pitney WR, Castaldi PA: Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982, 2:1246-1249.
10. 10 Kelton JG, Sheridan D, Santos A, et al.: Heparin-induced thrombocytopenia: laboratory studies. Blood 1988, 72:925-930.
11. 11 Greinacher A, Liebenhoff U, Kiefel V, et al.: Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication of high dose i.v. IgG. Thromb Haemost 1994, 71:641-645.
12. 12 Warkentin TE, Hayward CPM, Boshkov LK, et al.: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84:3691-3699.
13. 13 Warkentin TE, Sheppard JI: Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 1999, 10: 319-326. Heparin-induced thrombocytopenia antibodies are more effective than physiologic platelet agonists such as thrombin in causing platelets to generate procoagulant, platelet-derived microparticles.
14. 14 Warkentin TE, Elavathil LJ, Hayward CPM, et al.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127:804-812.
15. 15 Warkentin TE: Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998, 35 (Suppl. 5):17-25.
16. 16 Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93:81-88.
17. 17 Warkentin TE: Clinical picture of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000:43-80.
18. 18 Warkentin TE, Sikov WM, Lillicrap DP: Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999, 62:44-48. Warfarin therapy of HIT can be complicated by either venous limb gangrene or "classic" warfarin-induced skin necrosis.
19. 19 Warkentin TE, Levine MM, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
20. 20 Funk S, Eichler P, Albrecht D, et al.: Heparin-induced thrombocytopenia (HIT) in orthopedic patients: a prospective cohort trial comparing UFH and LMWH [abstract]. Ann Hematol 2000; 79(suppl):A92.
21. 21 Warkentin TE, Simpson PJ, Sheppard JI, et al.: Importance of patient population in the frequency of HIT: a comparison of activation and antigen assays [abstract]. Thromb Haemost 1999, 82 (Suppl.):363-364.
22. 22 Lee DP, Warkentin TE: Frequency of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker Inc., 2000;81-112.
23. 23 Warkentin TE, Kelton JG: Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT [abstract]. Blood 1998, 92 (Suppl. 1):182a.
24. 24 Warkentin TE: History of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000;1-15.
25. 25 Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-507.
26. 26 Nand S, Wong W, Yuen B, et al.: Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997, 56:12-16.
27. 27 Wallis DE, Workman DL, Lewis BE, et al.: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635. Large retrospective cohort study suggesting that early recognition of HIT and cessation of heparin are often complicated by thrombosis.
28. 28 Almeida JI, Coats R, Liem TK, Silver D: Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998, 27:309-316.
29. 29 Warkentin TE, Levine MN, Hirsh J, et al.: Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial [abstract]. Blood 1995, 86 (Suppl. 1):537a.
30. 30 Monreal M, Lafoz E, Casals A, et al.: Platelet count and venous thromboembolism: a useful test for suspected pulmonary embolism. Chest 1991, 100:1493-1496.
31. 31 Warkentin TE: Pseudoheparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000;245-260.
32. 32 Mustafa MH, Mispireta LA, Pierce LE: Occult pulmonary embolism presenting with thrombocytopenia and elevated fibrin split products. Am J Med 1989, 86:490-491.
33. 33 Stahl RL, Javid JP, Lackner H: Unrecognized pulmonary embolism presenting as disseminated intravascular coagulation. Am J Med 1984, 76:772-778.
34. 34 Popov D, Zarrabi MH, Foda H, Graber M: Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997, 29:449-452.
35. 35 Ling E, Warkentin TE: Intraoperative heparin flushes and acute heparin-induced thrombocytopenia. Anesthesiology 1998, 89:1567-1569.
36. 36 Hewitt RL, Akers DL, Leissinger CA, et al.: Concurrence of anaphylaxis and acute heparin-induced thrombocytopenia in a patient with heparin-induced antibodies. J Vasc Surg 1998, 28:561-565.
37. 37 Greinacher A, Völpel H, Janssens U, et al. for the HIT Investigators Group: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999, 99:73-80. First prospective treatment study of lepirudin suggesting efficacy in treatment of HIT-associated thrombosis.
38. 38 Greinacher A, Janssens U, Berg G, et al., for the Heparin-associated Thrombocytopenia Study (HAT) Investigators: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999, 100:587-593. Second prospective treatment study of lepirudin suggesting efficacy in treatment of HIT-associated thrombosis.
39. 39 Greinacher A, Eichler P, Lubenow N, et al.: Heparin-induced thrombocytopenia with thromboembolic complications: meta-anatysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; in press. Achieving target aPTT is important in minimizing bleeding complications in lepirudin treatment of HIT-associated thrombosis.
40. 40 Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Safety 1997, 17:325-341.
41. 41 Ranze O, Eichner A, Lubenow N, et al.: The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study [abstract]. Ann Hematol 2000, 79(suppl. 1):P198.
42. 42 Warkentin TE: Venous limb gangrene (VLG) complicating warfarin treatment of deep-vein thrombosis (DVT) in metastatic carcinoma [abstract]. Blood 1999, 94 (Suppl. 1):114b.
43. 43 Thomas D, Block AJ: Thrombocytopenia, cutaneous necrosis, and gangrene of the upper and lower extremities in a 35-year-old man. Chest 1992, 102:1578-1580.
44. 44 Gupta AK, Kovacs MJ, Sauder DN: Heparin-induced thrombocytopenia. Ann Pharmacother 1998, 32:55-59.
45. 45 Battey PM, Salam AA: Venous gangrene associated with heparin- induced thrombocytopenia. Surgery 1985, 97:618-620.
46. 46 Wallis DE, Quintos R, Wehrmacher W, Messmore H: Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999, 116:1333-1338.
47. 47 Greinacher A, Michels I, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: antibody is not heparin-specific. Thromb Haemost 1992, 67:545-549.
48. 48 Newman PM, Swanson RL, Chong BH: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998, 80: 292-297.
49. 49 Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998, 79:1-7.
50. 50 Greinacher A, Warkentin TE: Treatment of heparin-induced thrombocytopenia: an overview. In: Heparin-Induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000:261-290.
51. 51 Tardy B, Tardy-Poncet B, Fournel P, et al.: Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia [letter]. Thromb Haemost 1999, 82:1199-1200. Describes clinical strategy for management of isolated HIT.
52. 52 Chong BH: Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000:291-311.
53. 53 Greinacher A: Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker, 2000:313-338.
54. 54 Warkentin TE: Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross- reactivity (XR) of danaparoid for HIT-IgG [abstract]. Blood 1996, 88(Suppl 1):626a.
55. 55 Tardy-Poncet B, Tardy B, Reynaud J, et al.: Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999, 115:1616-1620. Large retrospective cohort study suggesting that danaparoid is safe and effective for managing HIT in critically ill patients.
56. 56 Chong BH: Low molecular weight heparinoid and heparin-induced thrombocytopenia [abstract]. Aust N Z J Med 1996, 26:331.
57. 57 Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993, 70:554-561.
58. 58 Hoechst Marion Roussel, prescribing information (as of March 1998) for Refludan™. HMR, The Pharmaceutical Company of Hoechst, Kansas City, MO.
59. 59 Eichler P, Greinacher A: Anti-hirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT) [abstract]. Ann Hematol 1996, 72 (Suppl.):A4.
60. 60 Song X, Huhle G, Wang L, et al.: Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999, 100:1528-1532.
61. 61 Huhle G, Hoffmann U, Song X, et al.: Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999, 106:195-201.